One Step Drug of Abuse Test

(Combo Strip)

For Forensic Use Only

INTENDED USE

The One Step Drug of Abuse Test is a lateral flow chromatographic immunoassay for the qualitative detection of Fentanyl and Xylazine in substance or urine at the following cut-off concentration:

| TEST | CALIBRATOR | CUT-OFF |
|--------------------|------------|----------|
| Fentanyl (FEN10) | Fentanyl | 10 ng/mL |
| Xylazine (XYL500) | Xylazine | 500ng/mL |

This assay provides only a preliminary qualitative test result. Use a more specific alternate guantitative analytical method to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) or Liquid chromatography/mass spectrometry (LC/MS) is the preferred confirmatory method.¹ Apply clinical and professional judgment to Fentanyl and Xylazine test result, particularly when a preliminary positive result is obtained

SUMMARY AND EXPLANATION OF THE TEST

The One Step Drug of Abuse Test is a competitive immunoassay utilizing highly specific reactions between antibodies and antigens for the detection of Fentanyl and Xylazine in substance or urine without the use of an instrument.

FENTANYL (FEN10)

Fentanyl is a potent, synthetic opioid analgesic with a rapid onset and short duration of action. It is a strong agonist at the μ -opioid receptors. Historically, it has been used to treat breakthrough pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic in combination with a benzodiazepine. Fentanyl is approximately 80 to 100 times more potent than morphine and roughly 15 to 20 times more potent than heroin. Fentanyl and its derivatives are used recreationally. Deaths have resulted from both recreational and improper medical use.

The FEN10 assay contained within the One Step Drug of Abuse Test yields a positive result when the concentration of Fentanyl in specimen exceeds 10 ng/mL

XYLAZINE (XYL500)

Xylazine is not a controlled substance; it is marketed as a veterinary drug and used as a sedative, analgesic and muscle relaxant. In humans, it could cause central nervous system depression, respiratory depression, bradycardia, hypotension, and even death. Most of the non-fatal cases required medical intervention. Over recent years xylazine has emerged as an adulterant in recreational drugs, such as heroin or speedball (a cocaine and heroin mixture). Its chronic use is reported to be associated with physical deterioration and skin ulceration. Literature shows some similar pharmacologic effects between xylazine and heroin in humans. These similar pharmacologic effects may create synergistic toxic effects in humans. Therefore, fatalities among drug users may increase due to the use of xylazine as an adulterant. Xylazine alone has proven harmful to humans and even more when it is combined with drugs of abuse

The XYL500 assay contained within the One Step Drug of Abuse Test yields a positive result when the concentration of Xylazine in specimen exceeds 500 ng/mL.

PRINCIPLE

The One Step Drug of Abuse Test is an immunoassay based on the principle of competitive binding. Drugs which may be present in the specimen compete against their respective drug conjugate for binding sites on their specific antibody. During testing, a specimen migrates upward by capillary action. A drug, if present in the specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.

A drug-positive specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug - negative specimen will generate a line in the test line region because of the absence of drug competition. To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The test contains a membrane strip coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to individual drug on the list in the Intended Use section.

PRECAUTIONS

For Forensic Use Only

- · Do not use after the expiration date.
- The test panel should remain in the sealed pouch until use. The test is for single use . · While urine is not classified by OSHA or the CDC as a biological hazard unless visibly contaminated with blood, the use of gloves is recommended to avoid unnecessary contact with the specimen.
- The used test device and the specimen should be discarded according to federal, state and local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 4-30° C (39-86° F). The test is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Substances or Urine Assav

If the substance you are testing is in liquid form, or if you are testing substances or urine, proceed to the respective Step 1(see directions below) which corresponds to your device. The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be allowed to settle to obtain a clear specimen for testing.

If the substance you are testing is in powder form, place substance in a container and add water to the substance and mix well. Proceed to the respective Step 1 (see directions below) which corresponds to your device.

If the substance you are testing is in pill format, crush or scrape some of the pill into a container. Add water to the substance and mix well. Proceed to the respective Step 1 (see directions below) which corresponds to your device.

MATERIALS

Materials Provided

· Test device · Desiccants · Package insert


Materials Required But Not Provided Timer · Disposable gloves

DIRECTIONS FOR USE


Allow the test device substance, or urine specimen to come to room temperature [15-30°C (59-86°F)] prior to testing.

[For Strip]

- 1) Remove the strip from the foil wrapper or the desiccated container (bring the container to the room temperature before opening to avoid condensation of moisture in container). Label the strip with patient or control identifications.
- 2) Immerse the strip into the prepared specimen with the arrow end pointing toward the urine. Do not cover over the MAX (maximum) line. You may leave the strip in the specimen or you may take the strip out after a minimum of 15 seconds in the specimen and lay the strip flatly on a non - absorptive clean surface.
- 3) Read result at 3 to 5 minutes. DO NOT READ RESULT AFTER 5 MINUTES.



INTERPRETATION OF RESULTS



(Please refer to the previous illustration)

NEGATIVE: Three lines appear.* One color line should be in the control region (C), and another apparent color line adjacent should be in the test region (XYL and FEN). This negative result indicates that the drug concentration is below the detectable level.

* NOTE: The shade of color in the test line region (XYL and FEN) will vary, but it should be considered negative whenever there is even a faint distinguishable color line.

POSITIVE: One color line appears in the control region (C). No line appears in the test region (XYL or FEN). This positive result indicates that the drug concentration is above the detectable level

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test cup. If the problem persists, discontinue using the lot immediately and contact your supplier.

QUALITY CONTROL

A procedural control is included in the test. A color line appearing in the control region (C) is considered an internal procedural control . It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

LIMITATIONS

- 1. The test provides only a qualitative, preliminary analytical result. A secondary analytical be used to obtain a confirmed result.Gaschromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.
- 2. There is a possibility that technical or procedural errors, as well as other interfering substances in the specimen may cause erroneous results.
- A Positive result does not indicate intoxication of the donor, the concentration of drug in the urine or the route of drug administration.
- 4. A Negative result may not necessarily indicate drug free urine. Negative results can be obtained when drug is present but below the cut - off level of the test.
- 5. Test does not distinguish between drugs of abuse and certain medications.
- 6. A positive test result may be obtained from certain foods or food supplements.
- 7. The test device is NOT intended to determine the purity, composition, or if the substance being examined is safe to use.
- 8. A positive or negative test result is NOT an indication that the substance being examined is safe to use. Many factors come into play when examining the samples. including but not limited to mixture of multiple substances, solubility, and pH of the
- 9. The test shall not encourage the use, supply, or production of illegal drugs or controlled substances in any way. The test is intended for harm reduction purposes. Follow the advice of your local harm reduction or public health agency.

10. Not for testing Cocaine

- 11. There is a possibility that technical or procedural errors as well as other substances and factors may interfere with the test strip (Liquid / Powder) cause false results.
- 12. A positive result indicates the presence of drugs only and does not indicate quantity
- 13. A negative result does not at any time rule out the presence of drugs, as they may be present below the minimum detection level of the test.

PERFORMANCE CHARACTERISTICS

Reproducibility For FEN10

Reproducibility studies were carried out using commercially available stock solutions of the drug analytes listed. The results are listed in the following table.

| FENTANYL CONCENTRATION (ng/mL) | TOTAL NUMBER OF DETERMINATIONS | RESULT | PRECISION |
|-----------------------------------|-----------------------------------|-------------|-----------|
| No Drug Present | 60 | 60 negative | >99% |
| 5 | 60 | 60 negative | >99% |
| 15 | 60 | 60 positive | >99% |

Reproducibility For XYL500

Reproducibility studies were carried out using commercially available stock solutions of the drug analytes listed. The results are listed in the following tables.

| FENTANYL CONCENTRATION (ng/mL) | TOTAL NUMBER OF DETERMINATIONS | RESULT | PRECISION |
|-----------------------------------|-----------------------------------|-------------|-----------|
| No Drug Present | 60 | 60 negative | >99% |
| 250 | 60 | 60 negative | >99% |
| 750 | 60 | 60 positive | >99% |

Analytical Sensitivity For FEN10

A drug-free substances or urine pool was spiked with drug at concentrations listed. The results are summarized below.

| DRUG CONCENTRATION | n | FEN | |
|--------------------|----|-----|----|
| CUT-OFF RANGE | | - | + |
| 0% Cut-Off | 30 | 30 | 0 |
| -50% Cut-Off | 30 | 30 | 0 |
| -25% Cut-Off | 30 | 30 | 0 |
| Cut-Off | 30 | 3 | 27 |
| +25% Cut-Off | 30 | 0 | 30 |
| +50% Cut-Off | 30 | 0 | 30 |

Analytical Sensitivity For XYL500

A drug-free urine pool was spiked with drugs at concentrations listed. The results are summarized below.

| DRUG CONCENTRATION | n | FEN | | |
|--------------------|----|-----|----|--|
| CUT-OFF RANGE | | - | + | |
| 0% Cut-Off | 30 | 30 | 0 | |
| -50% Cut-Off | 30 | 30 | 0 | |
| -25% Cut-Off | 30 | 30 | 0 | |
| Cut-Off | 30 | 2 | 28 | |
| +25% Cut-Off | 30 | 0 | 30 | |
| +50% Cut-Off | 30 | 0 | 30 | |

Analytical Sensitivity For FEN10

The following table lists the concentration of compounds (ng/mL) that were detected positive in substances or urine by the One Step Fentanyl Drug of Abuse Test at a read time 3 to 5 minutes.

| Compound Name | Positive result at | Cross- reactivity (%) |
|---|--------------------|--------------------------|
| Acetyl-a-methyl fentanyl | 50ng/ml | 20% |
| Acryl fentanyl | 40ng/ml | 25% |
| α-methyl fentanyl | 10ng/ml | 100% |
| Benzyl fentanyl | 25ng/ml | 40% |
| β-hydroxythio fentanyl | 10ng/ml | 100% |
| Cyclopropyl fentanyl | 10ng/ml | 100% |
| 4-Fluoroisobutyryl Fentanyl | 10000ng/ml | 0.1% |
| Methoxyacetyl fentanyl | 125ng/ml | 8% |
| 4-methoxybutyryl fentanyl (para) | 4000ng/ml | 0.25% |
| 4'-methyl acetyl fentanyl | 250ng/ml | 4% |
| 3'-methyl Fentanyl | 10ng/ml | 100% |
| N-methyl norfentanyl | 15ng/ml | 66.7% |
| o-Fluorofentanyl | 25ng/ml | 40% |
| p-Fluorobutyryl fentanyl | 20ng/ml | 50% |
| Tetrahydrofuran fentanyl | 5000ng/ml | 0.2% |
| 2-Thiofuranyl fentanyl | 500ng/ml | 2% |
| 4-Piperidone | 25000ng/ml | 0.04% |
| 2',4'-dimethoxy Fentanyl | 25ng/ml | 40% |
| 3',4'-dimethoxy Fentanyl | 5ng/ml | 200% |
| meta-fluoro Acrylfentanyl | 25ng/ml | 40% |
| para-chloro Furanyl fentanyl 3- furancarboxamide | 50ng/ml | 20% |
| Thiophene fentanyl 3- thiophenecarboxamide | 250ng/ml | 4% |
| 3'-Fluorofentanyl | 12.5ng/ml | 80% |
| ortho-fluoro Valeryl fentanyl | 5000ng/ml | 0.2% |
| 4-methyl Fentanyl | 50ng/ml | 20% |
| Cyclopropaneacetyl fentanyl | 25ng/ml | 40% |
| para-Chloroacetyl fentanyl | 50ng/ml | 20% |
| para-hydroxy Butyryl fentanyl | 15ng/ml | 66.7% |
| 2'-Fluoro ortho-Fluorofentanyl | 100ng/ml | 10% |
| meta-methoxy Furanyl fentanyl | 250ng/ml | 4% |
| 3'-fluoro ortho-Fluorofentanyl | 50ng/ml | 20% |
| 2',3'-dimethoxy Fentanyl | 10ng/ml | 100% |
| 2',6'-dimethoxy Fentanyl | 25ng/ml | 40% |
| 3',5'-dimethoxy Fentanyl | 2.5ng/ml | 400% |
| Acetyl norfentanyl | 1000ng/ml | 1% |

Analytical Specificity For XYL500

The following table lists the concentration of compounds (ng/mL) that were detected positive in urine by the One step Xylazine Test at a read time of 3 to 5 minutes.

| Drug | Concentration |
|---------------------------|-----------------------|
| Xylazine | Positive at 500ng/ml |
| Clonidine hydrochloride | Positive at 100µg/ml |
| Doxylamine | Positive at 50µg/ml |
| Diclofenac Sodium Salt | Positive at 2000µg/ml |
| Levamisole | Positive at 500µg/ml |
| Caffeine | Negative at ≤10mg/mL |
| Diphenhydramine | Negative at ≤30mg/ml |
| 4-Dimethylaminoantipyrine | Negative at ≤10mg/mL |
| Cocaine | Negative at ≤10mg/mL |
| Methamphetamine | Negative at ≤50mg/ml |
| MDMA | Negative at ≤50mg/ml |
| Fentanyl | Negative at ≤10mg/mL |
| Phenacetin | Negative at ≤10mg/ml |
| Phenelzine sulfate salt | Negative at ≤10mg/mL |
| Lidocaine | Positive at 10mg/ml |
| Quinine | Negative at ≤100µg/ml |
| Oxalic Acid | Negative at ≤10mg/mL |
| Oxymetazoline | Negative at ≤10mg/mL |
| Heroin | Negative at ≤10mg/mL |
| 21-Hydroxy progesterone | Negative at ≤10mg/mL |
| Ketoprofen | Negative at ≤10mg/mL |
| Acetaminophen | Negative at ≤10mg/mL |
| Benzocaine | Negative at ≤10mg/mL |
| Procaine | Negative at ≤10mg/mL |
| Theophylline | Negative at ≤10mg/mL |

EFFECT OF URINARY SPECIFIC GRAVITY

Urine samples of normal, high, and low specific gravity ranges from 1.000 - 1.025 were spiked with drug at 50% below and 50% above cut-off levels respectively and tested using One Step Fentanyl Drug of Abuse Test. The results demonstrate that varying ranges of specimen specific gravity do not interfere with the performance of the test.

EFFECT OF URINARY PH

The pH of an aliquoted negative urine pool was adjusted to pH ranges of 4.0, 5.0, 6.0, 7.0, 8.0 and 9.0, and spiked with drug at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the One Step Fentanyl Drug of Abuse Test. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

INTERFERENCE

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free substances or urine, or drug positive substances or urine containing Fentanyl.

The following compound shows no cross-reactivity when tested with the One Step Fentanyl Drug of Abuse Test at concentrations of $10 \mu g/ml$.

Carfentanil

The following compounds show no cross-reactivity when tested with the One Step Fentanyl Drug of Abuse Test at concentrations of 100µg/ml.

Acebutolo Acetopromazine-d6 Acetyl-L-cysteine Acetylsalicylic Acid (Aspirin) Acetaminophen O6-Acetylmorphine Acetazolamide N-Acetylprocainamide Acetone Acetophenetidin Albumin,Human recombinant Alprenolol hydrochloride Alprazolam Allopurinol Alphenal Amiloride Aminophenazon Amiodarone Hydrochloride Tablets Ampicinine(Ampicillin) Amitriptyline Aminophylline Amantadine Hydrochloride Amphotericin B Ammonium Chloride Amphetamine Sulfate Amikacin Amikacin sulfate p-Aminobenzoic Acid DL-Aminoglutethimide Anamycin sulfate Aniline Antipyrine Apomorphine Aprobarbital Aspartame L-Ascorbic Acid L-Aspartic Acid D-Aspartic Acid **DL-Aspartic Acid** Atenolo Atropine Baclofen Benzphetamine Barbituric Acid Berberine Benzocaine Benzyl alcohol Benzoylecogonine BenzovI fentanyI (PhenyI fentanyI) Bendroflumethiazide Beclomethasone Benzalkonium bromide Benzthiazide Benzylamine Hydrochloride Bisacody Brorphine Bromazepam Bupivacaine Buprenorphine Buprenorphine-3P-D-glucuronide Bupropion hydrochloride Buspirone Butacaine Butabarbital Butyrophenone Butethal Caffeine Carbamazepine Carisoprodol Cefaclor Ceftriaxone Cefotaxime Cefoxitin Cefuroxime Axetil (Zinnat) Cefadroxil Cephradine Chloroquine

Chlorpheniramine Chlorpromazine Chlorpropamide Chlorprothixene Chlorthalidone Chlorzoxazone Chloral Hydrate Cimetidine Cinchonidine Cinoxacin Cicosporin Citric acid Clenbuterol Hydrochloride Clindamycin Clobetasone Butyrate Clomipramine Clorazepate Dipotassium Clonazepam Clobazam Cloxacillin Cholesterol (-)-Cotinine Cocaethylene Cocaine Hydrochloride Codeine Creatinine Chlorothiazide Camphor Clonidine hydrochloride Canrenoic acid Captopri**l** Clozapine Chloramphenicol Cortisone a-Chymotrypsin Cetirizine Hydrochloride Tablets Cyclobenzaprine Hydrochloride L-Cystine Cyproheptadine Hydrochloride Cyclopentobarbital Chlorothiazide Camphor Clonidine hydrochloride Canrenoic acid Captopril Clozapine Chloramphenicol Cortisone a-Chymotrypsin Cetirizine Hydrochloride Tablets Dantrolene sodium Dextromethorphan hydrobromide Dexamethasone Deoxyepinephrine Deferoxamine Mesylate Despropionyl ortho-Fluorofentanyl Diazoxide Dieldrin Desipramine Desoximetasone Dimethy**l I**sosorbide Diazepam Diflorasone Diacetate Diflunisal Dipyridamole Dipyrone 5,5-Diphenylhydantoin D,L-3,4-Dihydroxymandelic acid Dihvdralazine Disopyramide Dopamine Dobutamine Doxepin Doxycycline Hytclate Doxylamine Droperido Ecgonine methylester

Ephedrine-(+/-) Ervthromycin Eserine Estazolam Estradiol, 17B-Estrio Estrone Estrone-3-sulfate Etoposide Ethacrynic Acid Ethambuto Ethyl-p-aminobenzoate Ethylenediamine Tetraacetic Etodolac Etonitazene Ethyl Morphine R(-)-Epinephrine Emetine dihvdro-chloride hvdrate Ethyl acetate Famotidine Fenfluramine Ferrous Sulfate Fenoprofen Flufenamic Acid Elunitrazenam Flunisolide Fluphenazine dihydrochloride Flurandrenolide Flurazepam Furosemide Gentamicin Sulfate Glutathione reduced Glybenclamide Griseofulvin Halcinonide Hemoglobin Heroin Hexachlorophene Hypnoval (Cyclobarbital) Hippuric Acid Histamine Hydralazine (1 R,9S)-(-)-p-Hydrastine Hydroflumethiazide Hydromorphone Hydrocodone Hydroxocobalamin hydrochloride a -Hydroxyhippuric acid Hydroxyzine dihydrochloride a-Hydroxyalprazolam Hydroxyprogesterone p-Hydroxymethamphetamine Hydrocortisone Hydrochlorothiazide (+/-)-4-Hydroxyamphetamine HCL Hydroxyurea Haloperidol Ibuprofen **II**fomifensine Imipramine Imidazole Indapamide Indomethacin Ipratropium Bromide Isonicotinic Acid Isoxsuprine Isoproterenol-(+/-) sotonitazene Ketamine Kynurenic Acid Labetalo Lactose Levorphano Lidocaine Lithium Carbonate Lorazepam glucuronide Mannito Maprotiline Mebendazole Meclofenamic Acid Medazepam Mefenamic Acid Melanin Meperidine Meprobamate Merperidine Metaraminol Methamphetamine

D-methamphetamine o-Methoxyanime HCL Methoxyphenamine Methylene Blue Methylphenidate Meticrane Metoclopromide Hydrochloride Metronidazole 4-Metylumbelliferyl B-D-glucuronide hydrate Mianserin Milrinone Minaprine Morphine Methyl saliylate Methoxyamine hydrochloride Metaproterenol hemisulfate salt Nabumetone Nadolol Nafcillin Nalbuphine Nalorphine hydrochloride Naphtho Naproxen Naphazoline hydrochloride 1-Naphthylacetic acid 1 Naloxone hydrochloride Nalmefene Neomycin Sulfate Nialamide Niacinamide (+/-) Nicotine Nimesulide Nitrazepam Nifedipine Nicotinic Acid Nitrofurantoin Norch ordiazepoxide Norclomipramine Nordiazepam Nordoxepin Norfloxacin Norethindrone Norpropoxyphene Noscapine Norcarfentani Norfludiazepam Nortriptyline Hydrochloride Nylidrin OxymorphoneOfloxacin Oxazepam Oxymetazoline Oxyphenbutazone Oxypurinol Octopamine Orphenadrine hydrochloride Oxalic Acid Pargyline Picrotoxin Potassium chloride Propionylpromazine Pancuronium Bromide Papaverine Paracetamol tablets Paclitaxel PCP Morpholine Anolog Pentobarbital Pentvlenetetrazole Pentoxifylline Perphenazine Phenelzine Penicillin Phenacetin Phencyclidine(PCP) Phenformin Pheniramine Phenobarbita**l** Phenothiazine Phenol Phenolphthalien Phentermine P-phenylene Phenylephrine-L Phenylbutazone Phenylethylamine

Phenylpropanolamine Phenvitoloxamine **Pilocarpine** Pimozide PiperidvIthiambutene Pipecolic Acid Piroxicam Potassium lodide Prazepam Prednisolone Acetate Pri**l**ocaine Primaquine diphosphate Primidone Proadifen Probenecid Procainamide hydrochloride Procaine Procyclidine Promazine Promethazine Propoxyphene,d-Propranolo Protriptyline Pseudoephedrine HCL Pyridine-2-Aldoxime Pyridoxine Pyrilamine 2, 3-pyridine dicarboxylic acid Ouinine Quinidine Ouinacrine Sodium chloride Ritodrine Roxithromycin tablets Ranitidine Riboflavin Salbutamol (Albuterol) Salicylic Acid Secobarbital Serotonin Sertaline Sodium Cromoglicate Sodium Formate Stearic magnesium Sulfamethazine Sulfamethoxazole Sulfisoxazole Sulindac Sulfathiazole Sulfanilamide Tamoxifen Citrate Tannic Acid Tenoxicam Terfenadine Acebutolol Hydrochloride

Terbutaline Tetraethylthiuram disulfide Tetracycline Thebaine Theobromine Thiamine Theophylline Tianeptine Tobramycin Tolazamide Tolbutamide Tolmetin Triprolidine Tramado Trazodone 2, 4, 6-trmethylbezamide Tropic Acid Tropine D/L-Tyrosine Trichloroacetic acid Trimipramine Tryptamine Trich**l**ormethiazide Trimethoprim L-Thyroxine Trifluoperazine D. L-Tryptophan Triazolam Trans-2-phenylcyclo-propylamine hvdrochloride Tyramine Uric Acid Urea Vancomycin HCL Venlafaxine hydrochloride Verapamil Vincamine Vanillic acid diethylamine Xylometazoline hydrochloride Yohimbine Zearalenone Zomepirac Zopiclone 4-Anilino-1-Boc-piperidine 2-fluoro Viminol 4-Anilino-1-benzylpiperidine AP-238 2,3-Benzodioxole fentanyl N-Benzyl-4-piperidone 4-Anilinopiperidine O-Desmethyl-cis-tramadol Despropionyl para-Fluoro fentanyl N-Phenethyl-4-piperidone(NPP) 4-ANPP AP-237 2-methyl AP-237

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing Xylazine. The following compounds show no cross-reactivity when tested with the One Step Xylazine Test at concentrations of 100µg / mL.

N-Acetylprocainamide Acetophenetidin Albumin, Human recombinant Alprazolam Alphenal Amoxicillin Ampicillin Amitriptyline Hydrochloride Tablets S(+)Amphetamine R(-)-Amphetamine Amobarbital (±)Amphetamine R-(-)-Apomorphine Aprobarbital Aspirin Aspartame L-Ascorbic Acid Atropine 6-Acetylmorphine Acetylsalicylic acid Benzphetamine

Benzilic acid SS Benzoic Acid Bilirubin, Mixed Isomers Bromazepam Brompheniramine maleate Buprenorphine Butalbital Butabarbital Cannabinol Cetirizine Hydrochloride Chlordiazepoxide HCL Chlorothiazide Chloroquine Chlorpheniramine Maleate Chloramphenicol ChloralHydrate Cholesterol Chlorothiazide Clomipramine Clomzepate dipotasium Clonazepam Clobazam Clozapine

(-) Cotinine Cocaethylene Codeine Cortisone Cyclopentobarbital Citalopram hydrobromide Dextromethorphan Desalkylflurazepam Desipramine Delorazepam Diazepam Diclofenac Sodium salt Dicvclomine Diflunisal Digoxin Dihydrocodeine HCL Dopamine Dihydromorphine Ecgonine methylester Ecgonine HCL Efavirenz Emetine dihydrochloride hydrate Ephedrine-(+/-) hydrochloride (-) -Ephedrine HCL [1R,2S] (-) Ephedrine Erythromycin Physostigmine Estazolam β-Estradiol (±)-EDDP Bata-D-glucuromicle EthylMorphine Fenoprofen Flunitrazepam Furosemide Gentisic acid D-Glucuronic acid Glutethimide Guaifenesin Gabapentin Hemoglobin porcine Hydralazine hydrochloride Hydromorphone Hydrocodone α-Hydroxyhippuric acid 21-Hydroxy progesterone p-Hydroxymethamphetamine Hydrocortisone Hydrochlorothiazide Ibuprofen Imipramine Isoxsuprine hydrochloride Isoproterenol Hydrochloride

Injection Ketamine hvdrochloride JWH-018 pantanoic acid JWH-073 butanoic acid Labetalol Hydrochloride Levorphanol Loperamide Hydrochloride Lormetazepam (±)-MDEA (±)-MDA Meprobamate (±)Methadone S(+)D-methamphetamine L-methamphetamine Methylphenidate (±)-MDPV Methyprylon Midazolam Morphine Morphine-3β-D-glucuronide Morphine sulfate salt solution Nalidixic acid Naloxone Naltrexone hydrochloride Nicotinamide (vitamin B3) Nimesulide Nitrazepam Nifedipine Norcodeine Nordiazepam Nordoxepin hydrochloride Norfloxacin Capsule Norethisterone Tablets d-Norpropoxyphene maleate salt Noscapine Nortriptyline Hydrochloride Noroxymorphone HCL Nylidrin hydrochloride Norchlordiazepoxide Norfentanyl Normorphine Oxymorphone Papaverine PCP Pentobarbital Pentazocine Perphenazine . Penicillin G Sodium salt Phenobarbital Phentermine HCL Phenylethylamine

BIBLIOGRAHY

- 1. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd ed. Davis: Biomedical Publications; 1982.
- 2. Hawks RL, Chiang CN, eds. Urine Testing for Drugs of Abuse. Rockville: Department of Health and Human Services, National Institute on Drug Abuse; 1986.
- 3. Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs. 53 Federal Register; 1988.
- McBay AJ. Drug-analysis technology--pitfalls and problems of drug testing. Clin Chem. 1987 Oct; 33 (11 Suppl): 33B-40B.
- Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan; 1980

Manufactured By:

W.H.P.M., Inc. 5358 Irwindale Ave. Irwindale, CA 91706 MADE IN USA www.whpm.com

DGP36197-1.0